Consistent network structure over time. by Tristan J. B. Cann (10692475)

“…Communities are labelled 1 − 5 in decreasing order of size, and colored blue, yellow, green, red and purple respectively. …”

Image1_LncRNA VPS9D1-AS1 Promotes Malignant Progression of Lung Adenocarcinoma by Targeting miRNA-30a-5p/KIF11 Axis.tif by Jiefeng Liu (9194412)

“…</p><p>Results: VPS9D1-AS1 and KIF11 were increased in LUAD, whereas miRNA-30a-5p was decreased. VPS9D1-AS1 promoted the malignant progression of LUAD cells and could sponge miRNA-30a-5p. …”

Table1_LncRNA VPS9D1-AS1 Promotes Malignant Progression of Lung Adenocarcinoma by Targeting miRNA-30a-5p/KIF11 Axis.xlsx by Jiefeng Liu (9194412)

“…</p><p>Results: VPS9D1-AS1 and KIF11 were increased in LUAD, whereas miRNA-30a-5p was decreased. VPS9D1-AS1 promoted the malignant progression of LUAD cells and could sponge miRNA-30a-5p. …”

Distribution of hookworm infections in different P/A/Ms in 2019 according to the national surveillance. by Hui-Hui Zhu (6506063)

The Impact of Prophylactic Dexamethasone on Nausea and Vomiting after Thyroidectomy: A Systematic Review and Meta-Analysis by Zhenhong Zou (645858)

“…Dexamethasone 8–10<b> </b>mg had a significantly greater effect for reducing the incidence of PONV than dexamethasone 1.25–5<b> </b>mg. …”

A Comparative Study of Neural and Mesenchymal Stem Cell-Based Carriers for Oncolytic Adenovirus in a Model of Malignant Glioma by Atique U. Ahmed (226456)

“…Loading oncolytic adenovirus into NSCs and MSCs also led to expression of both pro- and anti-inflammatory genes and decreased vector-mediated neuroinflammation. Our results indicate that, despite possessing a comparable migratory capacity, NSCs display superior therapeutic efficacy in the context of intracranial tumors. …”

Multiple trauma and hemorrhagic shock induce a transcriptional immune response. by Marc-Alexander Oestreich (13961375)

Temporal distributions of inscriptions and occupations using uniform 50-years-long timeblocks. by Vojtěch Kaše (6156971)

Viability of FTY720-treated T_CM A. by Rachel S. Resop (9238645)

During electrical stimulation the decrease in compound action potential (CAP), but not of ATP, is larger in <i>Plp</i>^null/y mice. by Andrea Trevisiol (9647910)

SDS-PAGE (10%) of culture supernatant of representative HESA-derived Tn5 mutants H28–35 (Table 1) cultured for 16 h. by Marion Schoof (11999106)

Histogram of gastroenteritis in a rural village, Kazakhstan, May–June 2021 (N = 154). by Madina Orysbayeva (14241331)

A T-test mean comparison of pre and post COVID-19 differences for selected variables. by Beshir Bedru Nasir (8218863)

Clinical outcome at 60 days based on SaFi, anakinra and a simplified SCOPE. by Ismael Francisco Aomar-Millán (14838595)

Image_10_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.t... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_1_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_4_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_3_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_8_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_6_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”